Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S A Factor

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Neurology|October 26, 1999
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystoniaA Brashear, M F Lew, D D Dykstra, et al.
Neurology|September 26, 1997
Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystoniaM F Lew, B T Adornato, D D Duane, et al.
The Pharmacogenomics Journal|October 4, 2012
A genetic basis for the variable effect of smoking/nicotine on Parkinson's diseaseE M Hill-Burns, N Singh, P Ganguly, et al.
Parkinsonism & Related Disorders|April 1, 2014
Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's diseaseA J H Moonen, A Wijers, A F G Leentjens, et al.
Archives of Neurology|July 25, 1998
Clinical presentation and pharmacological therapy in corticobasal degenerationK Kompoliti, C G Goetz, B F Boeve, et al.
Neurology|September 30, 2010
A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2D M Kay, C F Stevens, T H Hamza, et al.
Parkinsonism & Related Disorders|May 7, 2015
Association of cognitive domains with postural instability/gait disturbance in Parkinson's diseaseV E Kelly, C O Johnson, E L McGough, et al.
Neurology|April 13, 2012
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson diseaseI H Richard, M P McDermott, R Kurlan, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Neurology|October 26, 1999
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystoniaA Brashear, M F Lew, D D Dykstra, et al.
Neurology|September 26, 1997
Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystoniaM F Lew, B T Adornato, D D Duane, et al.
The Pharmacogenomics Journal|October 4, 2012
A genetic basis for the variable effect of smoking/nicotine on Parkinson's diseaseE M Hill-Burns, N Singh, P Ganguly, et al.
Parkinsonism & Related Disorders|April 1, 2014
Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's diseaseA J H Moonen, A Wijers, A F G Leentjens, et al.
Archives of Neurology|July 25, 1998
Clinical presentation and pharmacological therapy in corticobasal degenerationK Kompoliti, C G Goetz, B F Boeve, et al.
Neurology|September 30, 2010
A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2D M Kay, C F Stevens, T H Hamza, et al.
Parkinsonism & Related Disorders|May 7, 2015
Association of cognitive domains with postural instability/gait disturbance in Parkinson's diseaseV E Kelly, C O Johnson, E L McGough, et al.
Neurology|April 13, 2012
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson diseaseI H Richard, M P McDermott, R Kurlan, et al.
Pageof 8